WHO ICTRP trial
A prospective study of primary metastatic renal cell carcinoma treated with…
NL-OMON57224 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON57224 |
|---|---|
| Public title | A prospective study of primary metastatic renal cell carcinoma treated with immunecheckpoint inhibitors and cytoreductive nephrectomy vs primary tumour in place |
| Scientific title | A prospective study of primary metastatic renal cell carcinoma treated with immunecheckpoint inhibitors and cytoreductive nephrectomy vs primary tumour in place - PrimerX |
| Primary sponsor | Oncologie |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Netherlands |
| Conditions | Renal Cell Carcinoma renal malignancy;10038364;10038430;10038365 |
| Interventions | Cytoreductive nephrectomy |
| Registration date | Mar 14, 2024 |
| Target size | 750 |
| Secondary IDs | NL83948.018.23 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: